Keyword Tag Sort by


Categories: Vaccines HPV V503 Gardasil Medicine

Dr. Daron G. Ferris New HPV vaccine under study

Dr. Daron G. Ferris

AUGUSTA, Ga. – A new vaccine against nine of the most harmful strains of human papillomavirus is under study at the Medical College of Georgia.

The vaccine, a nine-valent called V503, is being compared with Gardasil, a quadrivalent vaccine already on the market that works against the two most deadly HPV types.

Gardasil, approved by the U.S. Food and Drug Administration in 2006, protects against HPV types 16 and 18, which cause about 70 percent of HPV-related cervical cancer cases, and types 6 and 11, which cause about 90 percent of genital wart cases.

The new drug could prevent infection from those four types and five other cancer-causing types, Dr. Ferris says.

“Women infected with those five types of HPV also have an increased risk of developing severe precancerous cervical disease and cervical cancer,” he says. “While genital warts go away on their own in most cases, cervical precancerous lesions are less likely to disappear without treatment.”

HPV is incurable and Gardasil is the only preventive treatment on the market, Dr. Ferris says. Treatments range from topical creams to surgical removal of precancerous lesions.

Like Gardasil, the new vaccine contains proteins that form virus-like particles that assemble into a hollow sphere resembling HPV’s protective coating.

“Since the sphere lacks the actual viral DNA on the inside, it cannot cause HPV,” Dr. Ferris says. “But the body is tricked into making antibodies to protect against the real thing.”

In the previous Gardasil studies, half of the subjects were given Gardasil while the other half got a placebo (saline water). In this study, the placebo is Gardasil, so both groups get a vaccine.

“Either they’ll be vaccinated against four or nine types of HPV,” Dr. Ferris says. “It’s a win-win situation.”

The initial target group for the new vaccine will be females age 9-26 because most HPV infections occur among 15- to 25-year-olds. Risks associated with the study may include injection site pain and swelling; pelvic discomfort during the exam; and/or vaginal bleeding in cases where a biopsy is needed for further examination.

Study participants will have five to11 office visits over seven months to three-and-a-half years that will include physical and pelvic exams; Pap smears to detect cancerous or precancerous changes of the cervix; and HPV testing.

The study is open to healthy, non-pregnant women age 16 to 26 with no history of abnormal Pap tests.

Contact: For more information, call Dr. Ferris’ office at 706-721-2535.

Source: Medical College of Georgia

Related News:

Pivotal study in The Lancet shows potential of Novartis vaccine... 14 January 2013, 01:56
Phase III results show that Bexsero induced a robust immune response when administered...

Assessment of HPV DNA Alone Insufficient to Identify HPV-driven... 19 September 2012, 14:50
Viral load and cancer-specific gene expression identified as potential markers....

New Study Confirms Erroneous Link Between XMRV and Prostate... 19 September 2012, 04:59
Study Confirms Erroneous Link Between Prostate Cancer and Retrovirus from Mice.A once-promising...

Anti-Cocaine Vaccine Described in Human Gene Therapy Journal 18 June 2012, 04:07
AAVrh.10-Mediated Expression of an Anti-Cocaine Antibody Mediates Persistent Passive...

Groundbreaking Discovery of the Cellular Origin of Cervical Cancer 12 June 2012, 06:18
A team of scientists from A*STAR’s Institute of Medical Biology (IMB) and Genome Institute of...

Skin Infection Sheds Light on Immune Cells Living in Our Skin 1 March 2012, 12:25
BOSTON, MA—Very recently, researchers discovered an important population of immune cells...

Pivotal study published in JAMA confirms potential of Novartis... 7 February 2012, 16:06
Data previously presented at ESPID annual meeting add to the body of evidence showing that...

Discovery of New Vaccine Approach for Treatment of Cancer 21 December 2011, 08:21
Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at...

A Step Towards New Vaccines for Most Important Chicken Parasite 14 October 2011, 05:07
Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC), among...

Scientists Reveal HIV Weakness 21 June 2011, 15:45
Vaccines that target newly identified viral protein sequences could be more effective than...